Kodiak Sciences Inc
Company Profile
Business description
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Contact
1250 Page Mill Road
Palo AltoCA94304
USAT: +1 650 281-0850
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
124
Stocks News & Analysis
stocks
Stop asking if there’s a stock market bubble. Ask this instead.
stocks
Are negative AI narratives holding this ASX share back?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,027.90 | 7.40 | -0.08% |
| CAC 40 | 8,367.33 | 17.54 | -0.21% |
| DAX 40 | 24,626.89 | 44.33 | -0.18% |
| Dow JONES (US) | 52,182.74 | 306.63 | 0.59% |
| FTSE 100 | 10,484.22 | 23.80 | -0.23% |
| HKSE | 23,001.56 | 25.12 | -0.11% |
| NASDAQ | 25,820.14 | 522.53 | 2.07% |
| Nikkei 225 | 70,125.17 | 657.06 | 0.95% |
| NZX 50 Index | 13,627.61 | 82.05 | 0.61% |
| S&P 500 | 7,440.43 | 86.41 | 1.18% |
| S&P/ASX 200 | 8,827.10 | 4.40 | -0.05% |
| SSE Composite Index | 4,059.66 | 14.24 | -0.35% |